GPR65 blockade may not uniformly remodel immune landscapes across all tumour regions and could inadvertently support cancer stem cell niches or create selection pressures that confer survival advantages to more aggressive cancer cells [97,99]. The gene discussed is GPR65; the disease is neoplasm.